Lurasidone Hydrochloride

Specification：20mg,40mg,60mg,80mg (Formulation strength)

Indications：
1.Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia
2.Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression)
3.Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression)

Origin：India

Batch Size：＞59kg

Registration status：
FDA：27570    A
CDE: Y20200000744  I

Advantage：
The formulation which used the same API has TA in US FDA, we can offer formulation Technology Transfer service.
Exclusive API, independent review in CDE